1. Intermediate hyperglycaemia 2. Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine
Conditions
Interventions
Current interventions as of 17/12/2020:
Community mobilisation through male and female community groups using a Participatory Learning and Action Cycle whereby groups themselves identify and prioritis
Sponsors
University College London Institute for Global Health
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 30 years and above 2. Permanent residents in one of the study clusters during the study period
Exclusion criteria
Exclusion criteria: 1. Aged under 30 years 2. Temporary residents in the study clusters 3. Individuals who decline to participate in the survey 4. Individuals who lack the capacity to consent to participate in the study 5. Currently self-reported as pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 17/12/2020: Combined prevalence of intermediate hyperglycaemia and diabetes among adults aged 30 years or older defined according to WHO fasting and 2-hour post ingestion of 75 g glucose load, plasma glucose cut-off categorisations for normoglycaemia, intermediate hyperglycaemia (impaired fasting glucose or impaired glucose tolerance), and type 2 diabetes mellitus. Blood glucose measures will be recorded from fasting and 2-hour post-glucose load whole blood samples obtained from finger prick capillaries among a random sample of adults in each of the study clusters using handheld glucometers. These measurements will be done once for each random sample of individuals. A new random sample will be taken at month 0 (before any intervention), and at month 18 (after intervention completion). Intervention and control data points will be compared. Previous primary outcome measure: Combined prevalence of intermediate hyperglycaemia and diabetes among adults aged 30 years or older defined according to WHO fasting and 2-hour post ingestion of 75 g glucose load, plasma glucose cut-off categorisations for normoglycaemia, intermediate hyperglycaemia (impaired fasting glucose or impaired glucose tolerance), and type 2 diabetes mellitus. Blood glucose measures will be recorded from fasting and 2-hour post-glucose load whole blood samples obtained from finger prick capillaries among a random sample of adults in each of the study clusters using handheld glucometers. These measurements will be done once for each random sample of individuals. A new random sample will be taken at month 0 (before any intervention), at month 12 (50% of clusters have received the intervention), and month 24 (100% of clusters have received the intervention). Intervention and control data points will be compared. | — |
Secondary
| Measure | Time frame |
|---|---|
| Updated 17/12/2020: All secondary outcomes will be measured in a random sample of adults in each of the study clusters. The information will be collected by interview once for each random sample of individuals, with a new random sample taken at month 0 (before any intervention), at month 18 (after intervention completion). Previous: All secondary outcomes will be measured in a random sample of adults in each of the study clusters. The information will be collected by interview once for each random sample of individuals, with a new random sample taken at month 0 (before any intervention), at month 12 (50% of clusters have received the intervention), and month 24 (100% of clusters have received the intervention). Current secondary outcome measures as of 06/03/2020: 1. Self-awareness of diabetic status. This is the proportion of participants with WHO defined type 2 diabetes according to fasting and 2-hour post ingestion of 75 g glucose load plasma glucose cut-offs or who report having been diagnosed with type 2 diabetes by a healthcare provider during an interviewer administered survey. 2. Physical activity assessed using questions adapted from the WHO Stepwise tool and the 2014 Bangladesh Demographic and Health Survey 3. Mean population diastolic and systolic blood pressure measured by study data collectors using the OMRON HBP 1100 Professional Blood Pressure Monitor (Kyoto, Japan). Two measurements will be taken at approximately 5-min intervals and the respondent’s blood pressure obtained by averaging these measurements. 4. Mean population body mass index calculated from participants' weight and height taken by study data collectors. Weight will be measured using a scale calibrated daily with a known weight. For height, participants will stand in an erect posture vertically touching the occiput, back, hip, and heels on the wall while gazing horizontally in front and keeping the tragus and lateral orbital margin in the same horizontal plane. 5. Mean population wais | — |
Countries
Bangladesh
Outcome results
None listed